日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations

粪便微生物组和代谢组特征的综合分析能够区分非肝硬化性NASH患者和健康对照人群。

Carr, Rotonya M; Li, Yun; Chau, Lillian; Friedman, Elliot S; Lee, Jung-Jin; Adorini, Luciano; Erickson, Mary; Zaru, Luna; Shringarpure, Reshma; MacConell, Leigh; Bittinger, Kyle; Li, Hongzhe; Wu, Gary D

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

奥贝胆酸与原发性胆汁性胆管炎患者的AST/血小板比值指数和GLOBE评分的改善相关。

Harms, Maren H; Hirschfield, Gideon M; Floreani, Annarosa; Mayo, Marlyn J; Parés, Albert; Liberman, Alexander; Malecha, Elizabeth Smoot; Pencek, Richard; MacConell, Leigh; Hansen, Bettina E

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

一项关于奥贝胆酸治疗原发性硬化性胆管炎的随机、安慰剂对照 II 期研究

Kowdley, Kris V; Vuppalanchi, Raj; Levy, Cynthia; Floreani, Annarosa; Andreone, Pietro; LaRusso, Nicholas F; Shrestha, Roshan; Trotter, James; Goldberg, David; Rushbrook, Simon; Hirschfield, Gideon M; Schiano, Thomas; Jin, Yuying; Pencek, Richard; MacConell, Leigh; Shapiro, David; Bowlus, Christopher L

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

奥贝胆酸治疗原发性胆汁性胆管炎患者可降低并稳定胆红素水平

Parés, Albert; Shiffman, Mitchell; Vargas, Victor; Invernizzi, Pietro; Malecha, Elizabeth S; Liberman, Alexander; MacConell, Leigh; Hirschfield, Gideon

Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis

GLOBE 和英国原发性胆汁性胆管炎风险评分在原发性胆汁性胆管炎患者试验队列中的临床应用

Carbone, Marco; Harms, Maren H; Lammers, Willem J; Marmon, Tonya; Pencek, Richard; MacConell, Leigh; Shapiro, David; Jones, David E; Mells, George F; Hansen, Bettina E

Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects

在健康受试者的 I 期研究中评估奥贝胆酸与咖啡因、咪达唑仑、华法林、右美沙芬、奥美拉唑、瑞舒伐他汀和地高辛之间的药代动力学相互作用

Edwards, Jeffrey E; Eliot, Lise; Parkinson, Andrew; Karan, Sharon; MacConell, Leigh

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

每周一次使用艾塞那肽治疗2型糖尿病患者,体重变化、血糖控制和心血管风险指标之间的关联:一项汇总分析

Blonde, Lawrence; Pencek, Richard; MacConell, Leigh

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

艾塞那肽每周一次治疗2型糖尿病患者的安全性和耐受性:一项纳入4328例患者的综合分析

MacConell, Leigh; Gurney, Kate; Malloy, Jaret; Zhou, Ming; Kolterman, Orville

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

每周一次艾塞那肽:3 年内持续改善血糖控制和心血管代谢指标

Macconell, Leigh; Pencek, Richard; Li, Yan; Maggs, David; Porter, Lisa

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes

比较2型糖尿病患者持续(每周一次艾塞那肽)或间歇(每日两次艾塞那肽)GLP-1受体激动剂治疗的安全性和耐受性

Ridge, T; Moretto, T; MacConell, L; Pencek, R; Han, J; Schulteis, C; Porter, L